类风湿关节炎患者临床缓解状态丧失的多参数风险表:STARTER 研究的事后分析
该事后分析基于 STARTER 研究纵向数据,纳入 389 例 DAS28 定义的类风湿关节炎缓解患者,按 OMERACT 指南行肌肉骨骼超声检查,采用 logistic 回归评估与疾病复发的关联。12 个月内 137 例(35%)出现复发,抗环瓜氨酸肽抗体阳性、基线持续临床缓解比例及滑膜能量多普勒信号存在与复发相关,据此构建多参数风险表,作者认为若经外部验证,该工具可能支持制定治疗策略。
要点
- 12 个月内 137/389 例(35%)DAS28 缓解的类风湿关节炎患者出现疾病复发。
- 复发组较持续缓解组抗环瓜氨酸肽抗体阳性率更高(75.9% vs 62.3%,P=0.007)。
- 复发组基线持续临床缓解比例更低(44.1% vs 68.5%,P=0.001),滑膜能量多普勒信号存在比例更高(58.4% vs 33.3%,P<0.001)。
核心结论
- 基于门诊可获得数据构建的多参数风险表可用于预测 DAS28 定义缓解的类风湿关节炎患者 12 个月内疾病复发,作者认为若经外部验证,该工具可能支持制定治疗策略。
研究设计与样本
- STARTER 研究的事后分析,纳入 389 例 DAS28 定义的类风湿关节炎缓解患者,均按 OMERACT 指南行肌肉骨骼超声检查,采用 logistic 回归评估变量与疾病复发的关联。
主要发现
- 12 个月内 137 例(35%)患者出现疾病复发。
- 复发组与持续缓解组抗环瓜氨酸肽抗体阳性率分别为 75.9% vs 62.3%(P=0.007)。
- 复发组与持续缓解组基线持续临床缓解比例分别为 44.1% vs 68.5%(P=0.001)。
- 复发组与持续缓解组滑膜能量多普勒信号存在比例分别为 58.4% vs 33.3%(P<0.001)。
- 上述三个特征的预测模型调整比值比为 3.064(95%CI 1.728-5.432)。
关键数值与推荐
- 风险表纳入抗环瓜氨酸肽抗体阳性、基线持续临床缓解及滑膜能量多普勒信号存在三个显著预测因子,用于预测入组后 12 个月内疾病复发。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This post-hoc analysis was carried out on data acquired in the longitudinal Sonographic Tenosynovitis Assessment in RheumaToid arthritis patiEnts in Remission (STARTER) study. Our primary aim was to determine the predictive clinical and musculoskeletal ultrasonographic (MSUS) features associated with disease flare in RA patients in clinical remission, while our secondary aim was to evaluate the probability of disease flare based on clinical and MSUS features. METHODS: We analysed data for a total of 389 RA patients in DAS28-defined remission. All patients underwent a MSUS examination according to the OMERACT guidelines. Logistic regression and results, presented as odds ratio and 95% CI, were used for the evaluation of the association between selected variables and disease flare. Significant clinical and MSUS features were incorporated into a risk table for predicting disease flare within at least 12 months of follow-up in patients with RA remission. RESULTS: Within 12 months, 137 (35%) RA patients experienced a disease flare. RA patients who experienced a flare disease differed from those with persistent remission in terms of ACPA positivity (75.9% vs 62.3%, respectively; P = 0.007), percentage of sustained clinical remission at baseline (44.1% vs 68.5%, respectively; P = 0.001) and synovium power Doppler signal presence (58.4% vs 33.3%, respectively; P < 0.001). Based on these results, these three features were considered in a predictive model of disease flare with an adjusted odds ratio of 3.064 (95% CI 1.728-5.432). Finally, a risk table was constructed including the three significant predictive factors of disease flare occurring within 12 months from the enrolment. CONCLUSION: An adaptive flare-prediction model tool, based on data available in outpatient settings, was developed as a multiparametric risk table. If confirmed by external validation, this tool might support the defining of therapeutic strategies in RA patients in DAS28-defined remission status.
引用
- Perniola S, Alivernini S, Gremese E, et al. A multiparametric risk table for loss of clinical remission status in patients with rheumatoid arthritis: a STARTER study post-hoc analysis. Rheumatology (Oxford). 2025. PMID: 38364299. doi:10.1093/rheumatology/keae094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。